Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01482091 · ClinicalTrials.gov registry record · Phase 4

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

A Phase 4 study of Pain and Anemia, Sickle Cell, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 4
Development phase
124
Enrollment target
1
Study location

NCT01482091 is a Phase 4 study of Pain and Anemia, Sickle Cell that has completed, run by Montefiore Medical Center. The registered enrollment target is 124 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01482091, a Phase 4 study of Pain and Anemia, Sickle Cell, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
124 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if intranasal fentanyl can decrease the pain of patients with sickle cell disease who present to the pediatric emergency department with a vaso-occlusive crisis.

Conditions Studied

Interventions

  • DRUG Normal Saline
  • DRUG Fentanyl Citrate

Study Locations (1)

New York

  • Children's Hospital at Montefiore - The Bronx

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2011-12
Phase Phase 4

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT01482091

The ClinicalTrials.gov registry entry for NCT01482091 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (59% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.

NCT01482091 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01482091 about?

NCT01482091 is a clinical study titled "Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis". The purpose of this study is to determine if intranasal fentanyl can decrease the pain of patients with sickle cell disease who present to the pediatric emergency department with a vaso-occlusive crisis.

What is the current status of trial NCT01482091?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 124 participants. The study started on 2011-12.

What conditions does trial NCT01482091 study?

This clinical trial studies the following conditions: Pain, Anemia, Sickle Cell.

What interventions are being tested in trial NCT01482091?

The interventions under investigation include: Normal Saline (DRUG), Fentanyl Citrate (DRUG).

Who is sponsoring clinical trial NCT01482091?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01482091 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.